The biotechnology company reported $1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.21. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.79 and a current ratio of 3.56.īio-Techne ( NASDAQ:TECH – Get Rating) last announced its quarterly earnings data on Wednesday, May 4th. The stock has a market capitalization of $13.51 billion, a P/E ratio of 62.84, a PEG ratio of 1.57 and a beta of 1.22. The company has a 50 day moving average price of $353.42 and a two-hundred day moving average price of $393.37. has a one year low of $318.07 and a one year high of $543.85.
Corporate insiders own 4.10% of the company’s stock. The disclosure for this sale can be found here. Following the transaction, the chief executive officer now owns 198,338 shares in the company, valued at approximately $72,393,370. The shares were sold at an average price of $365.00, for a total transaction of $1,862,960.00. Kummeth sold 5,104 shares of Bio-Techne stock in a transaction on Tuesday, June 7th. The acquisition was disclosed in a filing with the SEC, which is available at this link. Following the acquisition, the director now owns 10,106 shares of the company’s stock, valued at approximately $3,562,870.30. The shares were acquired at an average price of $352.55 per share, for a total transaction of $105,765.00.
Baumgartner bought 300 shares of Bio-Techne stock in a transaction that occurred on Tuesday, May 10th. In other Bio-Techne news, Director Robert V. The transaction was disclosed in a filing with the SEC, which is available through this link. Following the purchase, the director now directly owns 10,106 shares of the company’s stock, valued at $3,562,870.30. The stock was bought at an average cost of $352.55 per share, with a total value of $105,765.00. Baumgartner acquired 300 shares of the stock in a transaction dated Tuesday, May 10th. 94.36% of the stock is currently owned by institutional investors and hedge funds. Champlain Investment Partners LLC now owns 423,950 shares of the biotechnology company’s stock worth $219,326,000 after purchasing an additional 31,658 shares during the last quarter. Finally, Champlain Investment Partners LLC raised its position in shares of Bio-Techne by 8.1% during the 4th quarter. now owns 489,904 shares of the biotechnology company’s stock worth $253,447,000 after purchasing an additional 37,150 shares during the last quarter. raised its position in shares of Bio-Techne by 8.2% during the 4th quarter. Marshall Wace LLP now owns 580,835 shares of the biotechnology company’s stock worth $300,491,000 after purchasing an additional 350,215 shares during the last quarter. Marshall Wace LLP raised its position in shares of Bio-Techne by 151.9% during the 4th quarter. Geode Capital Management LLC now owns 762,953 shares of the biotechnology company’s stock valued at $393,692,000 after acquiring an additional 30,699 shares during the period. Geode Capital Management LLC lifted its position in shares of Bio-Techne by 4.2% during the 4th quarter. State Street Corp now owns 1,608,213 shares of the biotechnology company’s stock valued at $831,993,000 after acquiring an additional 73,760 shares during the period. State Street Corp lifted its position in shares of Bio-Techne by 4.8% during the 4th quarter. Truist Financial Corp’s holdings in Bio-Techne were worth $3,453,000 as of its most recent filing with the Securities & Exchange Commission.Ī number of other hedge funds and other institutional investors also recently modified their holdings of the stock. The firm owned 7,971 shares of the biotechnology company’s stock after selling 73 shares during the period. ( NASDAQ:TECH – Get Rating) by 0.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. Truist Financial Corp lowered its position in Bio-Techne Co.
0 kommentar(er)
